News
HMTXF
0.055
NaN%
--
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Newsfile · 1d ago
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Newsfile · 08/12 12:23
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Newsfile · 07/30 21:57
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Newsfile · 07/28 16:14
Hemostemix Grants Stock Options
Newsfile · 07/22 20:50
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Newsfile · 07/08 14:08
Hemostemix Closes $360,000 First Tranche of Private Placement
Newsfile · 06/26 12:47
Hemostemix' $1,000,000 Private Placement and Update
Newsfile · 06/17 21:22
Hemostemix Leadership Attending Abundance360 Summit
Newsfile · 03/09 15:23
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Newsfile · 02/03 13:55
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Newsfile · 12/31/2025 19:38
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Newsfile · 12/23/2025 14:10
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Newsfile · 12/11/2025 14:40
Hemostemix Grants Stock Options
Newsfile · 12/11/2025 13:57
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Newsfile · 12/10/2025 16:17
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Newsfile · 12/04/2025 14:10
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Newsfile · 12/03/2025 19:05
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Newsfile · 12/02/2025 14:10
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Newsfile · 11/26/2025 21:21
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Newsfile · 11/20/2025 14:00
More
Webull provides a variety of real-time HMTXF stock news. You can receive the latest news about Hemostemix through multiple platforms. This information may help you make smarter investment decisions.
About HMTXF
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.